DR Congo begins Ebola vaccine rollout for health workers

A health consortium comprising the World Health Organization, the African Centres for Disease Control and the ministries of health in several affected nations announced that 50,000 frontline health workers will receive a newly developed vaccine targeting a distinct strain of Ebola virus. The immunisation campaign, slated to begin next month, focuses on personnel who are most likely to encounter the virus during outbreak response, including clinicians, laboratory technicians and community health volunteers. The vaccine, produced by a partnership of biotech firms, is designed to protect against the Sudan ebolavirus, a variant that has caused sporadic flare‑ups in East Africa and for which no licensed prophylactic has previously been available.

Concurrently, a one‑year clinical trial enrolling 20,000 of the vaccinated staff will assess the jab’s safety, immunogenicity and durability of protection. Participants will undergo scheduled follow‑up visits, blood sampling and health monitoring at designated sites, with interim analyses planned at six months. Study results are expected to inform regulatory approval processes and guide future rollout strategies across the continent. Health officials emphasized that the trial’s outcomes will be critical for expanding vaccine access should the strain re‑emerge, and they will continue to coordinate surveillance and response efforts in collaboration with international partners.